Canaccord Genuity Starts Maze Therapeutics and Quoin at Buy
Canaccord Genuity initiated coverage of Maze Therapeutics and Quoin Pharmaceuticals with a Buy rating, according to Dow Jones Newswires, citing Benzinga data.
- published
- in the api
- on the website
on the website stories appear 15 minutes after publication, in the api at once. connect the api →
what happened
Dow Jones Newswires reports that analysts at Canaccord Genuity began coverage of Maze Therapeutics and Quoin Pharmaceuticals and assigned both companies a Buy rating. The report references Benzinga's analyst ratings data.
The two reports were published a few minutes apart on October 19, 2026. The text does not include price targets or financial figures for either company.
why it matters
Initial bank ratings on small biotechnology companies usually move individual stocks and have little effect on the broader market. Investors should note that such ratings do not, by themselves, change a company's financial results.
tags
instruments
sources
- Maze Therapeutics Initiated at Buy by Canaccord Genuity — Dow Jones Newswires, 19 October 2026 at 12:26 UTC
- Quoin Pharmaceuticals Initiated at Buy by Canaccord Genuity — Dow Jones Newswires, 19 October 2026 at 12:23 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
on the website stories appear 15 minutes after publication, in the api at once.
get stories in real time ↗